Quarterly Financial Data (Details) - USD ($) $ / shares in Units, shares in Millions	3 Months Ended																				6 Months Ended					12 Months Ended
	Dec. 31, 2015		Sep. 26, 2015		Jun. 27, 2015		Mar. 28, 2015		Dec. 27, 2014		Sep. 27, 2014		Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Dec. 31, 2015		Dec. 27, 2014	Dec. 28, 2013		Jun. 27, 2015		Jun. 28, 2014	Jun. 29, 2013
Sales Revenue, Goods, Net	$ 1,424,800,000		$ 1,344,700,000		$ 1,531,600,000		$ 1,049,100,000		$ 1,071,700,000		$ 951,500,000		$ 1,144,200,000		$ 1,004,200,000		$ 979,000,000		$ 933,400,000		$ 2,769,500,000		$ 2,023,100,000			$ 4,603,900,000		$ 4,060,800,000	$ 3,539,800,000
Net sales																					2,769,500,000	[1]		$ 4,060,800,000	[1]	4,603,900,000	[1]	4,060,800,000	3,539,800,000	[1]
Gross profit	559,300,000		548,800,000		628,100,000		378,800,000		383,800,000		321,800,000		415,700,000		315,000,000		360,700,000		356,300,000		1,108,100,000		705,500,000			1,712,500,000		1,447,700,000	1,280,000,000
Net income (loss)	$ (107,000,000)	[2]	$ 112,600,000	[3]	$ 56,400,000	[4]	$ (94,900,000)	[5]	$ 70,200,000	[6]	$ 96,300,000		$ 131,700,000	[7]	$ 48,100,000	[8]	$ (86,000,000)	[9]	$ 111,400,000	[10]	$ 5,600,000		$ 166,500,000			$ 128,000,000		$ 205,300,000	$ 441,900,000
Earnings (loss) per share:
Earnings (loss) per share, basic	$ (0.74)	[2],[11]	$ 0.77	[3],[11]	$ 0.39	[4],[11]	$ (0.67)	[5],[11]	$ 0.52	[6],[11]	$ 0.72	[11]	$ 0.98	[7],[11]	$ 0.36	[8],[11]	$ (0.87)	[9],[11]	$ 1.18	[10],[11]	$ 0.04		$ 1.23			$ 0.92		$ 1.78	$ 4.71
Earnings (loss) per share, diluted	$ (0.74)	[2],[11]	$ 0.77	[3],[11]	$ 0.38	[4],[11]	$ (0.67)	[5],[11]	$ 0.51	[6],[11]	$ 0.72	[11]	$ 0.98	[7],[11]	$ 0.36	[8],[11]	$ (0.87)	[9],[11]	$ 1.18	[10],[11]	$ 0.04		$ 1.23			$ 0.92		$ 1.77	$ 4.68
Weighted average shares outstanding
Basic	144.9		146.3		146.3		140.8		136.3		133.9		133.8		133.7		98.7		94.2		145.6		135.1			139.3		115.1	93.9
Diluted	144.9		146.9		146.8		140.8		136.8		134.4		134.3		134.3		98.7		94.7		146.1		135.6			139.8		115.6	94.5
Selected Quarterly Financial Information [Abstract]
Business acquisition, transaction costs																	$ 103,200,000		$ 12,000,000					$ 103,200,000
Goodwill impairment charge																					$ 0					$ 6,800,000		$ 0	$ 0
Derivative, loss on derivative							$ 258,200,000		$ 64,700,000												0					326,400,000		0	0
Net loss from equity method investment																					(7,100,000)					(9,900,000)		(8,700,000)
Proceeds from collaborators									12,500,000
Inventory step-up					$ 15,600,000
Cost of services, licenses and maintenance agreements					18,000,000				10,000,000
Restructuring	$ 24,700,000												$ 10,500,000		$ 19,500,000		14,900,000				26,900,000		$ 4,200,000			5,100,000		47,000,000	2,900,000
Available-for-sale Securities, Gross Realized Gain (Loss)	10,700,000																				10,700,000
Legal fees	71,300,000		$ 15,600,000		13,400,000
Impairment charges																					215,600,000		0			0		0	0
Business combination, acquisition related costs					$ 18,500,000				17,800,000
Loss on extinguishment of debt									$ 9,600,000								$ 165,800,000				(900,000)		$ (9,600,000)			(10,500,000)		(165,800,000)	$ 0
Texas Medicaid [Member]
Selected Quarterly Financial Information [Abstract]
Loss contingency accrual							24,000,000						$ 15,000,000															$ 15,000,000
Omega [Member]
Selected Quarterly Financial Information [Abstract]
Business combination, acquisition related costs							$ 18,600,000
Omega [Member]
Selected Quarterly Financial Information [Abstract]
Business combination, acquisition related costs																										$ 387,000,000
Omega [Member] | Brands [Member]
Selected Quarterly Financial Information [Abstract]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	185,100,000																				185,100,000
Operating Expense [Member] | Discontinued Operations, Held-for-sale [Member] | API [Member]
Selected Quarterly Financial Information [Abstract]
Impairment charges	$ 29,000,000																				$ 29,000,000

[1] Amounts may not cross-foot due to rounding.

[2] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.

[3] Includes Mylan defense-related fees of $15.6 million.

[4] Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees.Twelve Months Ended June 28, 2014FirstQuarter(2) SecondQuarter(3) ThirdQuarter(4) FourthQuarter(5)Net sales$933.4 $979.0 $1,004.2 $1,144.2Gross profit$356.3 $360.7 $315.0 $415.7Net income (loss)$111.4 $(86.0) $48.1 $131.7Earnings (loss) per share(1): Basic$1.18 $(0.87) $0.36 $0.98Diluted$1.18 $(0.87) $0.36 $0.98Weighted average shares outstanding Basic94.2 98.7 133.7 133.8Diluted94.7 98.7 134.3 134.3

[5] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million.

[6] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million

[7] Includes a loss contingency of $15.0 million related to Texas Medicaid and restructuring charges totaling $10.5 million

[8] Includes restructuring charges totaling $19.5 million

[9] Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, and restructuring charges totaling $14.9 million

[10] Includes Elan transactions costs of $12.0 million

[11] The sum of individual per share amounts may not equal due to rounding.